AzTrials
AzTrials

Wound HealNCT04834817

Effect of Combined Red and Near Infrared Light-emitting Diode (LED) Therapy on Tissue Regeneration Post Laser Treatment

A study testing Celluma POD in people with Wound Heal, run by University of California, Irvine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the effect of light therapy on wound healing after laser treatment. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Wound Heal
What is being tested?
Celluma POD
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteUnited States
Study dates
1 Apr 2021to 30 Mar 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 years or older with no active cutaneous disease on bilateral ventral biceps, close to the axilla.
  • Subjects shall have given written informed consent for both the LED therapy and for clinical photography.

Who cannot join

  • Patients will be excluded if any of the exclusion criteria applies
  • Subjects refuse to give informed consent for either the phototherapy or the clinical photography.
  • Subjects have previous photosensitivity problems (solar urticaria, etc.).
  • Subjects are taking any systemic drug or applying any topical drug with known photosensitizing properties.
  • Subjects taking any systemic drug with known immunosuppressant properties.
  • Subjects applying any medications to the research site (inner biceps, close to the axilla).
Show all 11Show fewer
  • Subjects have medical or psychosocial conditions associated with a risk of poor protocol compliance.
  • Subjects are smokers or have smoked within the last 30 days prior to the trial.
  • Subjects have epilepsy or a history of seizures
  • Subjects currently taking cortisone injections or any other kind of steroid injections(s)
  • Subjects with known cancer tumor in the treatment area or metastasis

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UCI Beckman Laser Institute and Medical Clinic

    Irvine, California, 92697

Other trials in United States

About this study

Official title: The Effect of Combined Red and Near Infrared Light-emitting Diode (LED) Therapy on Tissue Regeneration Post Laser Treatment

The purpose of this study is to evaluate the effect of light therapy on wound healing after laser treatment.

Read the detailed description

This study sets out to evaluate the effect of a combination of near infrared (830 nm) red (633 nm) and blue (465nm) light-emitting diode (LED) therapy on wound healing after laser application.

Conditions
Wound Heal
Being tested
Celluma POD

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Celluma PODDevice

    A blue and near infrared handheld LED device

Study groups in NCT04834817
Study groupRoleWhat they receive
LED treatmentExperimentalLED treatment with Celluma POD device after laser test area
Receives: Device: Celluma POD
ControlNo interventionNo treatment after laser test area

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Days to Healing

    The primary endpoint of this study is time and days to complete healing of the treatment sites. Clinical grading shall be by blinded assessment.

    Measured: Assessed from Day 0 to Day 55, up to 56 days

Secondary outcomes (1)
  1. Pain Level

    A secondary outcome measure will be post-treatment pain on a 11-point Lickert scale from 0-10. Higher scores mean a worse outcome.

    Measured: Assessed from Day 0 to Day 13, up to 14 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Apr 2021
  2. Study start1 Apr 2021
  3. Primary completion30 Mar 2024
  4. Study completion30 Mar 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a split-person study design where each participant has one arm with the intervention and the other arm that is control.
Masking
None (open label)
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04834817
Sponsor's protocol ID
20216401
Status last verified
Apr 2025
First submitted
4 Apr 2021
Last updated
13 Apr 2025
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Celluma POD in people with Wound Heal, run by University of California, Irvine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Apr 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Days to Healing (time frame: Assessed from Day 0 to Day 55, up to 56 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in